RETIGABINE ( DrugBank: Retigabine )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 2 |
| 144 | レノックス・ガストー症候群 | 4 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-001431-20-NL (EUCTR) | 17/08/2015 | 21/04/2015 | Trial to look at the nerve conductance in patients with ALS, with and without Riluzole or Retigabine. | A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor nerve excitability measurements in patients with ALS. - Peripheral motor nerve excitability study in patients with ALS | Amytrophic Lateral Sclerosis MedDRA version: 18.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rilutek 50 mg film-coated tablets Product Name: Rilutek INN or Proposed INN: RILUZOLE Trade Name: Trobalt Product Name: Trobalt INN or Proposed INN: RETIGABINE | Centre for Human Drug Research | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Netherlands | |||
| 2 | NCT02450552 (ClinicalTrials.gov) | June 2015 | 19/5/2015 | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Ezogabine;Drug: Placebo | Brian Wainger | ALS Association;GlaxoSmithKline;Harvard University;Massachusetts General Hospital | Completed | 18 Years | 80 Years | All | 65 | Phase 2 | United States |
144. レノックス・ガストー症候群
臨床試験数 : 111 / 薬物数 : 72 - (DrugBank : 14) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 61
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01668654 (ClinicalTrials.gov) | September 4, 2012 | 17/5/2012 | Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS | RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects With Partial Onset Seizures (>= 12 Years Old) and Subjects With Lennox-Gastaut Syndrome (>=12 Years Old) | Epilepsy | Drug: retigabine/ezogabine | GlaxoSmithKline | Bausch Health Americas, Inc. | Terminated | 12 Years | 29 Years | All | 4 | Phase 3 | United States |
| 2 | NCT01494584 (ClinicalTrials.gov) | July 25, 2012 | 1/12/2011 | Study in Pediatric Subjects With Epilepsy | Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome | Epilepsy | Drug: ezogabine/retigabine | GlaxoSmithKline | Bausch Health Americas, Inc. | Terminated | 12 Years | 17 Years | All | 5 | Phase 2 | United States |
| 3 | EUCTR2012-001132-60-Outside-EU/EEA (EUCTR) | 09/03/2012 | Study in pediatric subjects with epilepsy | Open-label, multiple dose study to evaluate thepharmacokinetics, safety and tolerability of ezogabine/retigabineas adjunctive treatment in subjects aged from 12 years to lessthan 18 years with partial onset seizures or Lennox-Gastautsyndrome | Uncontrolled partial onset seizures or Lennox Gastaut Syndrome MedDRA version: 14.1;Level: PT;Classification code 10061334;Term: Partial seizures;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Potiga Product Name: Retigabine/Ezogabine Product Code: GW582892 INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) Product Name: Retigabine/Ezogabine INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) Product Name: Retigabine/Ezogabine INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) | GlaxoSmithKline R&D Limited | NULL | NA | Female: yes Male: yes | 16 | United States | ||||
| 4 | EUCTR2010-020154-33-Outside-EU/EEA (EUCTR) | 09/03/2012 | Long-term Open-label Evaluation of Retigabine in Pediatric Subjects with Epilepsy | RTG113388, a Long-term, Open-label Safety Extension Study ofRetigabine/Ezogabine in Pediatric Subjects with Partial OnsetSeizures(=12 years old) and Subjects with Lennox-GastautSyndrome (=12 years old) - Long-term Open-label Safety Extension Study of Retigabine/Ezogabine in subjects >=12yrs with POS/LGS | Uncontrolled partial onset seizures or Lennox Gastaut Syndrome MedDRA version: 14.1;Level: PT;Classification code 10061334;Term: Partial seizures;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: RETIGABINE/EZOGABINE Product Code: GW582892 INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) Trade Name: Potiga Product Name: RETIGABINE/EZOGABINE Product Code: GW582892 INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US only) Product Name: RETIGABINE/EZOGABINE Product Code: GW582892 INN or Proposed INN: RETIGABINE Other descriptive name: EZOGABINE (US ONLY) | GlaxoSmithKline R&D Limited | NULL | NA | Female: yes Male: yes | 500 | United States |